Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

Shanghai Hile Bio-Technology Co Ltd

603718:SHH

Shanghai Hile Bio-Technology Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)8.49
  • Today's Change0.77 / 9.97%
  • Shares traded26.68m
  • 1 Year change-26.37%
  • Beta2.0978
Data delayed at least 15 minutes, as of Nov 06 2024 07:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SHANGHAI HILE BIO-TECHNOLOGY CO., LTD. is principally engaged in the research & development, production and sales of veterinary biological products. The Company’s products mainly include escherichia coli (K88 and K99) gene modified vaccines for piglets, inactivated; porcine reproductive and respiratory syndrome vaccines, live and swine infectious atrophic rhinitis vaccines, inactivated; newcastle disease mild vaccines, living; newcastle disease, infectious bronchitis, egg drop syndrome’76 vaccines, inactivated and infectious bronchitis vaccines, living, among others. The Company distributes its products mainly in China.

  • Revenue in CNY (TTM)220.55m
  • Net income in CNY8.35m
  • Incorporated1981
  • Employees295.00
  • Location
    Shanghai Hile Bio-Technology Co LtdNo. 6720Jinhai Highway, Fengxian DistrictSHANGHAI 200021ChinaCHN
  • Phone+86 2 160890892
  • Fax+86 2 160890800
  • Websitehttp://www.hile-bio.com
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
603718:SHH since
announced
Transaction
value
Shaanxi Reshine Biotechnology Co LtdDeal completed12 Jun 202412 Jun 2024Deal completed21.29%128.89m
Data delayed at least 15 minutes, as of Nov 06 2024 07:00 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Jinyao Pharmaceutical Co Ltd3.52bn152.00m4.75bn2.68k31.231.55--1.350.1390.1393.222.790.5742.439.061,313,392.003.391.915.653.4041.7946.335.903.310.953614.680.18944.402.559.28230.60-4.22-9.589.21
Jiangsu Jibeier Pharmaceutical Co Ltd887.17m238.58m4.86bn1.45k19.472.16--5.481.251.254.6411.310.38482.993.78613,955.4010.349.7711.1610.6687.9988.4426.8623.299.03--0.001430.6831.4912.1641.6517.79112.78--
Shouyao Holdings Co Ltd4.03m-209.50m5.05bn185.00--5.87--1,254.60-1.41-1.410.02715.790.00380.16165.0321,779.19-19.57-37.24-21.64-42.6395.4896.03-5,199.60-2,251.777.06--0.0087--186.18-23.51-6.76--34.59--
Shanghai Hile Bio-Technology Co Ltd220.55m8.35m5.08bn295.00667.243.99--23.030.01160.01160.3371.930.13791.262.06747,619.900.02211.730.02782.4748.6850.440.160610.372.92--0.050423.89-19.76-1.11-48.3024.17-41.3223.47
Sinotherapeutics Inc449.12m109.57m5.17bn260.0047.214.18--11.520.24170.24170.99072.730.32282.505.201,727,366.007.88--8.54--53.66--24.40--7.95--0.00002--21.13---34.29------
Hainan Huluwa Pharmaceutical Grop Co Ltd1.82bn112.88m5.34bn2.47k47.324.63--2.930.28210.28214.552.890.63232.493.22737,841.704.095.816.249.7853.9158.016.487.030.757312.480.531621.7425.7514.1324.291.1646.37--
Hunan Fangsheng Pharmaceutical Co Ltd1.76bn272.96m5.40bn1.69k19.703.39--3.070.62440.62444.053.630.55131.436.701,044,835.008.345.3914.839.3769.2866.9115.128.950.4736--0.316146.47-9.129.15-34.6420.6823.914.75
Data as of Nov 06 2024. Currency figures normalised to Shanghai Hile Bio-Technology Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

0.90%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 02 Oct 20241.77m0.28%
China Southern Asset Management Co., Ltd.as of 30 Jun 20241.51m0.23%
China Asset Management Co., Ltd.as of 30 Jun 2024847.80k0.13%
GF Fund Management Co., Ltd.as of 30 Jun 2024704.40k0.11%
Fullgoal Fund Management Co., Ltd.as of 30 Jun 2024327.10k0.05%
Western Asset Management Co. Pty Ltd.as of 30 Jun 2024230.10k0.04%
E Fund Management Co., Ltd.as of 30 Jun 2024152.20k0.02%
SSgA Funds Management, Inc.as of 03 Oct 2024127.40k0.02%
Hwabao WP Fund Management Co., Ltd.as of 30 Jun 202454.89k0.01%
HuaAn Fund Management Co., Ltd.as of 30 Jun 202437.80k0.01%
More ▼
Data from 30 Jun 2024 - 27 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.